Management of Nosocomial Pneumonia in Critical Care Settings

Nosocomial pneumonia remains a leading cause of morbidity and mortality in the intensive care unit, encompassing hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). Management hinges on prompt recognition, risk stratification for multidrug-resistant organisms and initiation of appropriate empirical antibiotic therapy. Early-phase approaches incorporate clinical assessment, radiological imaging and rapid molecular or culture-based diagnostics to identify causative pathogens. Empirical regimens are tailored according to local resistance patterns and individual patient risk factors, with subsequent de-escalation based on microbiology results. Pharmacokinetic and pharmacodynamic optimisation—through extended or continuous infusions of beta-lactams and adjunctive aerosolised agents—serves to maximise antimicrobial exposure. Supportive care addresses ventilatory strategies, fluid management and prevention of organ dysfunction. Concurrent implementation of infection control practices, such as hand hygiene, ventilator care bundles and antibiotic stewardship, is essential to reduce incidence and curb the emergence of resistance. Interdisciplinary collaboration among intensivists, microbiologists, pharmacists and nursing staff underpins both therapeutic and preventive efforts, while quality metrics and electronic surveillance inform continuous improvement in outcomes.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Management of Nosocomial Pneumonia in Critical Care Settings publication trend

The graph below shows the total number of articles in management of nosocomial pneumonia in critical care settings across all publications each year (not limited to Nature Index journals).

Technical terms

Hospital-acquired pneumonia (HAP): Pneumonia occurring ≥48 hours after hospital admission in patients not on mechanical ventilation.

Ventilator-associated pneumonia (VAP): Pneumonia developing ≥48 hours after endotracheal intubation and initiation of mechanical ventilation.

Multidrug-resistant organisms (MDROs): Pathogens resistant to one or more classes of antibiotics, complicating empirical therapy choices.

Empirical antibiotic therapy: Initial broad-spectrum treatment begun before pathogen identification, based on clinical judgement and local resistance data.

Antibiotic stewardship: Coordinated interventions to optimise antibiotic use, minimise resistance and improve patient outcomes.

References

1. Efficacy and safety of antibiotics targeting Gram-negative bacteria in nosocomial pneumonia: a systematic review and Bayesian network meta-analysis. Annals of Intensive Care (2024).
2. Update of the treatment of nosocomial pneumonia in the ICU. Critical Care (2020).
3. Effect of ICU quality control indicators on VAP incidence rate and mortality: a retrospective study of 1267 hospitals in China. Critical Care (2022).